Learn about the latest findings in leukemia, lung cancer and precision oncology

In the era of CDK4/6 inhibitors, the RxFINE-Low (EA1242) trial will evaluate whether chemotherapy provides additional benefit for patients with low genomic risk but high anatomic risk

A significant barrier to increasing oncology trial participation is a physical mismatch between sites with appropriate trial options and the locations where patients live and seek care. In order to re...

The American Cancer Society Cancer Action Network (ACS CAN) today expressed deep concern following media reports of a new planned executive order placing greater political control over research grant ...

Learn how ECOG-ACRIN is using an innovative artificial intelligence (AI) model to create more accurate recurrence risk predictions in patients with early-stage breast cancer.

Showcasing the center's commitment to training oncology researchers and improving patient outcomes through impactful cancer clinical trials

ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline.    

Researchers have analyzed annual survival data between AYA patients aged 15-39 years and patients in younger and older age groups between 1975 and 2017.

Today, the House passed a continuing resolution (CR) to fund the federal government through mid-December.

The August 2026 edition of “Unboxing Cancer News” highlights a transmissible cancer, federal- vs. industry-funded clinical trials, and more.

Read more about the findings for this cancer clinical study for patients with newly diagnosed multiple myeloma

Read about the latest discoveries in brain tumors, breast cancer, kidney cancer, lung cancer, Merkel cell carcinoma, and precision oncology

An analysis by Stand up for Science found that the White House Office of Management and Budget’s recently proposed rule, “Regulation for Federal Financial Assistance,” if finalized, could result in te...

AbstractPurpose:. Targeted next-generation sequencing (NGS) of cell-free DNA (cfDNA) enables comprehensive molecular profiling and can guide the selection of genotype-targeted therapies. However, the ...

Stanford Cancer Institute deputy director recognized for advancing lung cancer treatment and research.

NYU Langone Health’s Perlmutter Cancer Center experts presented clinical findings and research at the 2026 American Society of Clinical Oncology Annual Meeting.

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in ...

The Association for Clinical Oncology (ASCO) is asking congressional appropriators to allocate $51.3 billion to the National Institutes of Health (NIH) for Fiscal Year (FY) 2027.

Unlike many cancers, colorectal cancer has become more lethal for people at younger ages. Doctors are sleuthing out why.

A preview of the upcoming Spring Group Meeting, a recap of AACR 2026, and a call for respectful disagreement

PKCδ and CD25 assemble a complex for negative feedback control of tyrosine kinase signaling in acute leukemia cells.

Dr Naomi Haas discusses the feasibility of neoadjuvant therapy in RCC, highlighting the PROSPER trial's results and its role in treating unresectable disease.

Today, the administration released its Fiscal Year 2027 budget request, which proposes a 12% cut to the National Institutes of Health (NIH) and modest increase for the National Cancer Institute (NCI)....

Learn what is smoldering myeloma and about the first treatment approved by the FDA to prevent its progression to active multiple myeloma.

Study chair Dr. Monika Joshi and co-chair Dr. Petros Grivas discuss this trial that aims to improve outcomes for patients with anti-PD(L)1-resistant advanced urothelial cancer.